NOVO INTEGRATED SCIENCES INC (NVOS)
US67011T3005 - Common Stock
NVOS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 116 industry peers in the Health Care Providers & Services industry. NVOS may be in some trouble as it scores bad on both profitability and health. NVOS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NVOS has reported negative net income.
In the past year NVOS has reported a negative cash flow from operations.
In the past 5 years NVOS always reported negative net income.
NVOS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NVOS's Return On Assets of -37.48% is on the low side compared to the rest of the industry. NVOS is outperformed by 85.34% of its industry peers.
With a Return On Equity value of -59.20%, NVOS is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.48% | ||
| ROE | -59.2% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-27.97%
ROE(3y)-70.22%
ROE(5y)-45.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVOS's Gross Margin of 39.50% is fine compared to the rest of the industry. NVOS outperforms 66.38% of its industry peers.
NVOS's Gross Margin has been stable in the last couple of years.
NVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y0.48%
2. Health
2.1 Basic Checks
NVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NVOS has been increased compared to 1 year ago.
The number of shares outstanding for NVOS has been increased compared to 5 years ago.
NVOS has a better debt/assets ratio than last year.
2.2 Solvency
NVOS has an Altman-Z score of -2.94. This is a bad value and indicates that NVOS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVOS (-2.94) is worse than 82.76% of its industry peers.
NVOS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
NVOS has a Debt to Equity ratio of 0.07. This is in the better half of the industry: NVOS outperforms 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.94 |
ROIC/WACCN/A
WACC7.83%
2.3 Liquidity
NVOS has a Current Ratio of 0.62. This is a bad value and indicates that NVOS is not financially healthy enough and could expect problems in meeting its short term obligations.
NVOS has a Current ratio of 0.62. This is amonst the worse of the industry: NVOS underperforms 87.93% of its industry peers.
A Quick Ratio of 0.51 indicates that NVOS may have some problems paying its short term obligations.
NVOS has a worse Quick ratio (0.51) than 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.62 | ||
| Quick Ratio | 0.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 89.54% over the past year.
NVOS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.79%.
NVOS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.18% yearly.
EPS 1Y (TTM)89.54%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q75.88%
Revenue 1Y (TTM)8.79%
Revenue growth 3Y16.95%
Revenue growth 5Y7.18%
Revenue growth Q2Q13.78%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NVOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NVOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVO INTEGRATED SCIENCES INC
NASDAQ:NVOS (4/19/2024, 7:07:23 PM)
After market: 0.46 +0.01 (+1.95%)0.4512
-0.02 (-3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.60M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.48% | ||
| ROE | -59.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.62 | ||
| Quick Ratio | 0.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)89.54%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.79%
Revenue growth 3Y16.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y